董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steve Brandt | 男 | Director | 61 | 未披露 | 未持股 | 2017-04-13 |
| Jon W. Salveson | 男 | Director | 52 | 9.00万美元 | 未持股 | 2017-04-13 |
| Gregory D. Waller | 男 | Director | 67 | 9.00万美元 | 未持股 | 2017-04-13 |
| Warren S. Watson | 男 | Director | 65 | 9.00万美元 | 未持股 | 2017-04-13 |
| John L. Erb | 男 | Chief Executive Officer, President, Chairman of the Board, Director | 68 | 121.41万美元 | 未持股 | 2017-04-13 |
| Matthew E. Likens | 男 | Director | 64 | 未披露 | 未持股 | 2017-04-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Claudia Drayton | 女 | Chief Financial Officer, Secretary | 49 | 41.08万美元 | 未持股 | 2017-04-13 |
| John L. Erb | 男 | Chief Executive Officer, President, Chairman of the Board, Director | 68 | 121.41万美元 | 未持股 | 2017-04-13 |
董事简历
中英对照 | 中文 | 英文- Steve Brandt
-
Steve Brandt自2017年2月起担任公司董事。Brandt先生于2004年11月至2015年10月受雇于Thoratec Corporation，担任Vice President全球销售与市场营销，全球销售Vice President和Vice President国际销售。在加入Thoratec之前，Brandt先生从2002年10月到2004年11月担任CHF Solutions的Vice President销售和营销，从2000年11月到2002年10月担任St.Jude Medical心血管外科部门的Vice President全球营销。Brandt先生在富兰克林·皮尔斯学院（Franklin Pierce College）获得学士学位。
Steve Brandt has served as a director of the Company since February 2017. Mr. Brandt was employed by Thoratec Corporation from November 2004 to October 2015 serving as Vice President Global Sales and Marketing, Vice President of Global Sales and Vice President International Sales. Prior to Thoratec, Mr. Brandt was Vice President Sales & Marketing for CHF Solutions from October 2002 to November 2004 and Vice President Global Marketing, Cardiovascular Surgery Division for St. Jude Medical from November 2000 to October 2002. Mr. Brandt received his B.S. from Franklin Pierce College. - Steve Brandt自2017年2月起担任公司董事。Brandt先生于2004年11月至2015年10月受雇于Thoratec Corporation，担任Vice President全球销售与市场营销，全球销售Vice President和Vice President国际销售。在加入Thoratec之前，Brandt先生从2002年10月到2004年11月担任CHF Solutions的Vice President销售和营销，从2000年11月到2002年10月担任St.Jude Medical心血管外科部门的Vice President全球营销。Brandt先生在富兰克林·皮尔斯学院（Franklin Pierce College）获得学士学位。
- Steve Brandt has served as a director of the Company since February 2017. Mr. Brandt was employed by Thoratec Corporation from November 2004 to October 2015 serving as Vice President Global Sales and Marketing, Vice President of Global Sales and Vice President International Sales. Prior to Thoratec, Mr. Brandt was Vice President Sales & Marketing for CHF Solutions from October 2002 to November 2004 and Vice President Global Marketing, Cardiovascular Surgery Division for St. Jude Medical from November 2000 to October 2002. Mr. Brandt received his B.S. from Franklin Pierce College.
- Jon W. Salveson
-
Jon W. Salveson，自2012年5月起，他一直是我们的董事。他是纽约证交所上市公司Piper Jaffray Companies 的投资银行副主席和医疗保健投资银行集团主席。1993年，他加入Piper Jaffray，当一名助理；1999年当选为常务董事；2001年，被任命为Piper Jaffray的国际医疗保健银行集团的总裁；2004年，他被任命为Piper Jaffray的投资银行的全球总裁以及执行委员会成员；2010年7月，担任他现在的职务，投资银行副主席。他任职于达斯达克上市公司Sunshine Heart公司的董事会。他取得了圣奥拉夫学院的肄业证书和西北大学凯洛格管理学院金融硕士学位。
Jon W. Salveson has served as a director of CryoLife since May 2012. Mr. Salveson is the Vice Chairman, Investment Banking and Chairman of the Healthcare Investment Banking Group at Piper Sandler Companies NYSE: PIPR ("Piper Sandler"), formerly Piper Jaffray Companies, a U.S. investment bank and asset management firm. Mr. Salveson has served in his present position as Vice Chairman, Investment Banking since July 2010. Mr. Salveson was appointed Global Head of Investment Banking and a member of the Executive Committee of Piper Jaffray in 2004. He joined Piper Jaffray in 1993 as an associate, was elected Managing Director in 1999 and was named the Group Head of Piper Jaffray’s international healthcare investment banking group in 2001. Mr. Salveson also serves on the Board of Directors of CHF Solutions, Inc. (NASDAQ: CHFS), an early-stage medical device company. Mr. Salveson recently served on the board of Asklepios Biopharmaceuticals, Inc., a private company specializing in gene therapy technologies, which was acquired by Bayer AG (ETR: BAYN) in 2020. Mr. Salveson received his undergraduate degree from St. Olaf College in 1987 and an M.M.M. in finance from the Kellogg Graduate School of Management at Northwestern University. - Jon W. Salveson，自2012年5月起，他一直是我们的董事。他是纽约证交所上市公司Piper Jaffray Companies 的投资银行副主席和医疗保健投资银行集团主席。1993年，他加入Piper Jaffray，当一名助理；1999年当选为常务董事；2001年，被任命为Piper Jaffray的国际医疗保健银行集团的总裁；2004年，他被任命为Piper Jaffray的投资银行的全球总裁以及执行委员会成员；2010年7月，担任他现在的职务，投资银行副主席。他任职于达斯达克上市公司Sunshine Heart公司的董事会。他取得了圣奥拉夫学院的肄业证书和西北大学凯洛格管理学院金融硕士学位。
- Jon W. Salveson has served as a director of CryoLife since May 2012. Mr. Salveson is the Vice Chairman, Investment Banking and Chairman of the Healthcare Investment Banking Group at Piper Sandler Companies NYSE: PIPR ("Piper Sandler"), formerly Piper Jaffray Companies, a U.S. investment bank and asset management firm. Mr. Salveson has served in his present position as Vice Chairman, Investment Banking since July 2010. Mr. Salveson was appointed Global Head of Investment Banking and a member of the Executive Committee of Piper Jaffray in 2004. He joined Piper Jaffray in 1993 as an associate, was elected Managing Director in 1999 and was named the Group Head of Piper Jaffray’s international healthcare investment banking group in 2001. Mr. Salveson also serves on the Board of Directors of CHF Solutions, Inc. (NASDAQ: CHFS), an early-stage medical device company. Mr. Salveson recently served on the board of Asklepios Biopharmaceuticals, Inc., a private company specializing in gene therapy technologies, which was acquired by Bayer AG (ETR: BAYN) in 2020. Mr. Salveson received his undergraduate degree from St. Olaf College in 1987 and an M.M.M. in finance from the Kellogg Graduate School of Management at Northwestern University.
- Gregory D. Waller
-
Gregory D. Waller ，他是Sunshine Heart公司的董事（2011年8月以来）。他也任职Endologix Corporation（上市公司）的董事会，目前担任审计委员会主席和提名和治理委员会成员，也是Ulthera公司（一个私营公司，销售超声波设备，用于非侵入性眉部）的首席财务官。从2006年3月到2011年4月，他曾担任Universal Building Products公司（混凝土施工配件制造商）的首席财务官。他曾担任Sybron Dental Specialties公司（牙科产品消费品的制造商和销售商）的财务副总裁、首席财务官和财务主管（从1993年8月到2005年5月退休）。他也曾担任Kerr公司、Ormco Corporation、Metrex公司的副总裁兼财务主管。他于1980年12月加入Ormco Corporation，担任副总裁、总会计师。他也曾担任Kerr European公司的运营副总裁（从1989年7月到1993年8月）。他持有加州州立大学富勒顿分校（California State University, Fullerton）的工商管理硕士学位（会计）。他也曾任职几家私人公司的董事，涉及Alsius Corporation（一个上市公司，担任审计委员会主席和薪酬委员会的成员（从2007年6月到2009年9月被Zoll Medical Corporation收购）、 Biolase Technology公司（一家上市公司，担任审计委员会的主席）（从2009年10月到2010年8月）、 Cardiogenesis Corporation（公开交易的公司，公开交易的公司）、（从2007年4月到2011年5月被Cryolife公司收购）、Clarient公司（上市公司，于2010年12月被General Electric Company收购，担任审计委员会主席、薪酬和公司治理委员会的成员）（从2006年12月到2010年12月），SenoRx公司（一个于2010年7月被C.R.Bard公司收购的上市公司，担任审计委员会主席）（从2006年5月到2010年7月）。
Gregory D. Waller has served on our board of directors since November 2003. From October 2011 to April 2015 Mr. Waller was Chief Financial Officer of Ulthera Corp., a manufacturer of ultrasound equipment used to tighten and tone skin. Prior to that, from March 2006 to April 2011 Mr. Waller was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories. Mr. Waller served as Vice President-Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement from Syborn in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller joined Ormco Corporation in December 1980 as Vice President and Controller and served as Vice President of Kerr European Operations from July 1989 to August 1993. Mr. Waller also served on the board of directors and audit committee of Cardiogenesis Corporation, a publicly-traded company until its acquisition by Cryolife in 2011. Mr. Waller also served on the boards of directors of Alsius Corporation, a publicly-traded company, from June 2007 to September 2009 until its acquisition by Zoll, Biolase Technology, Inc., a publicly-traded company, from October 2009 to August 2010 Clarient, Inc., a publicly-traded company which was acquired by General Electric Company in December 2010 and SenoRx, Inc., a publicly-traded company which was acquired by C.R. Bard, Inc. in July 2010. Mr. Waller also serves on the boards of CHF Solutions and Arcadia Bioscience Corporation, both publicly-traded companies. Mr. Waller has an M.B.A. with a concentration in Accounting from California State University, Fullerton and a B.A. in Political Science from California State University, Fullerton. - Gregory D. Waller ，他是Sunshine Heart公司的董事（2011年8月以来）。他也任职Endologix Corporation（上市公司）的董事会，目前担任审计委员会主席和提名和治理委员会成员，也是Ulthera公司（一个私营公司，销售超声波设备，用于非侵入性眉部）的首席财务官。从2006年3月到2011年4月，他曾担任Universal Building Products公司（混凝土施工配件制造商）的首席财务官。他曾担任Sybron Dental Specialties公司（牙科产品消费品的制造商和销售商）的财务副总裁、首席财务官和财务主管（从1993年8月到2005年5月退休）。他也曾担任Kerr公司、Ormco Corporation、Metrex公司的副总裁兼财务主管。他于1980年12月加入Ormco Corporation，担任副总裁、总会计师。他也曾担任Kerr European公司的运营副总裁（从1989年7月到1993年8月）。他持有加州州立大学富勒顿分校（California State University, Fullerton）的工商管理硕士学位（会计）。他也曾任职几家私人公司的董事，涉及Alsius Corporation（一个上市公司，担任审计委员会主席和薪酬委员会的成员（从2007年6月到2009年9月被Zoll Medical Corporation收购）、 Biolase Technology公司（一家上市公司，担任审计委员会的主席）（从2009年10月到2010年8月）、 Cardiogenesis Corporation（公开交易的公司，公开交易的公司）、（从2007年4月到2011年5月被Cryolife公司收购）、Clarient公司（上市公司，于2010年12月被General Electric Company收购，担任审计委员会主席、薪酬和公司治理委员会的成员）（从2006年12月到2010年12月），SenoRx公司（一个于2010年7月被C.R.Bard公司收购的上市公司，担任审计委员会主席）（从2006年5月到2010年7月）。
- Gregory D. Waller has served on our board of directors since November 2003. From October 2011 to April 2015 Mr. Waller was Chief Financial Officer of Ulthera Corp., a manufacturer of ultrasound equipment used to tighten and tone skin. Prior to that, from March 2006 to April 2011 Mr. Waller was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories. Mr. Waller served as Vice President-Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement from Syborn in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller joined Ormco Corporation in December 1980 as Vice President and Controller and served as Vice President of Kerr European Operations from July 1989 to August 1993. Mr. Waller also served on the board of directors and audit committee of Cardiogenesis Corporation, a publicly-traded company until its acquisition by Cryolife in 2011. Mr. Waller also served on the boards of directors of Alsius Corporation, a publicly-traded company, from June 2007 to September 2009 until its acquisition by Zoll, Biolase Technology, Inc., a publicly-traded company, from October 2009 to August 2010 Clarient, Inc., a publicly-traded company which was acquired by General Electric Company in December 2010 and SenoRx, Inc., a publicly-traded company which was acquired by C.R. Bard, Inc. in July 2010. Mr. Waller also serves on the boards of CHF Solutions and Arcadia Bioscience Corporation, both publicly-traded companies. Mr. Waller has an M.B.A. with a concentration in Accounting from California State University, Fullerton and a B.A. in Political Science from California State University, Fullerton.
- Warren S. Watson
-
Warren S. Watson，他是Sunshine Heart公司的董事（2013年1月以来）。他是一位高管，拥有35多年的医疗设备领域经验。1982年以来，他曾一直担任Citizens Independent Bank of St. Louis Park, Minnesota（社区银行有四个分支机构，拥有3亿美元的资产）的董事。从2010年到2012年，他曾担任Cameron Health公司（医疗技术公司，专注于皮下植入式复律器和去纤颤器设备）的执行主席。从2004年到2009年，他曾担任CardioMems公司（新公司，专注于肺动脉压力监测患者的心力衰竭）的董事。从2002年到2009年，他曾担任Cardiac Rhythm Management（一个组织，领导全世界超过1800的专业人士）的研发副总裁，也曾担任美敦力公司企业研究与发展委员会（the Medtronic Corporate Research and Development Council）的主席。从2002年到2007年，他曾担任CardioRhythm公司（位于圣何塞市）的副总裁兼总经理，负责心脏消融术业务。
Warren S. Watson has served as a director of Sunshine Heart since January 2013. From 1982 to 2014 Mr. Watson served on the board of directors of Citizens Independent Bank of St. Louis Park, Minnesota, a community bank with four branches and $300 million in assets. From 2010 to 2012 he served as executive chairman of Cameron Health Inc., a medical technology company focused on subcutaneous implantable cardioverter and defibrillator devices. From 2004 to 2009 Mr. Watson served as a director for CardioMems, Inc., a start-up company focused on pulmonary artery pressure monitoring for patients with heart failure. From 2002 to 2009 Mr. Watson served as vice president of Cardiac Rhythm Management Research and Development, an organization leading over 1800 professionals worldwide; he also served as chair of the Medtronic Corporate Research and Development Council during his tenure with that organization. From 2002 to 2007 Mr. Watson served as vice president and general manager of the San Jose-based CardioRhythm cardiac ablation business. - Warren S. Watson，他是Sunshine Heart公司的董事（2013年1月以来）。他是一位高管，拥有35多年的医疗设备领域经验。1982年以来，他曾一直担任Citizens Independent Bank of St. Louis Park, Minnesota（社区银行有四个分支机构，拥有3亿美元的资产）的董事。从2010年到2012年，他曾担任Cameron Health公司（医疗技术公司，专注于皮下植入式复律器和去纤颤器设备）的执行主席。从2004年到2009年，他曾担任CardioMems公司（新公司，专注于肺动脉压力监测患者的心力衰竭）的董事。从2002年到2009年，他曾担任Cardiac Rhythm Management（一个组织，领导全世界超过1800的专业人士）的研发副总裁，也曾担任美敦力公司企业研究与发展委员会（the Medtronic Corporate Research and Development Council）的主席。从2002年到2007年，他曾担任CardioRhythm公司（位于圣何塞市）的副总裁兼总经理，负责心脏消融术业务。
- Warren S. Watson has served as a director of Sunshine Heart since January 2013. From 1982 to 2014 Mr. Watson served on the board of directors of Citizens Independent Bank of St. Louis Park, Minnesota, a community bank with four branches and $300 million in assets. From 2010 to 2012 he served as executive chairman of Cameron Health Inc., a medical technology company focused on subcutaneous implantable cardioverter and defibrillator devices. From 2004 to 2009 Mr. Watson served as a director for CardioMems, Inc., a start-up company focused on pulmonary artery pressure monitoring for patients with heart failure. From 2002 to 2009 Mr. Watson served as vice president of Cardiac Rhythm Management Research and Development, an organization leading over 1800 professionals worldwide; he also served as chair of the Medtronic Corporate Research and Development Council during his tenure with that organization. From 2002 to 2007 Mr. Watson served as vice president and general manager of the San Jose-based CardioRhythm cardiac ablation business.
- John L. Erb
-
John L. Erb ，他一直担任Sunshine Heart公司的董事（2012年9月以来），以及董事会主席（2012年10月以来）。他目前担任 Cardia Access公司（医疗设备公司，参与开发新设备用于治疗心脏病）的首席执行官（2007年2月以来）。他于2007年担任CHF Solutions公司（一个医疗设备公司，参与开发、生产和销售治疗充血性心力衰竭的设备）的执行董事会主席。从2001年到2006年，他是CHF Solutions公司的首席执行官。此前，他曾担任IntraTherapeutics公司（医疗设备公司，参与开发、制造和分销外围血管支架）的总裁兼首席执行官（从1997年到2001年）。此前，他曾担任Schneider Worldwide公司（Pfizer公司的一个部门）的全球运营副总裁。他曾担任SenoRx公司（上市公司）的董事（从2001年12月到2010年7月），也曾担任CryoCath Technologies公司（加拿大上市公司）的董事（从2000年10月到2008年12月）。他目前担任Cardia Access公司、Osprey Medical公司（澳大利亚证券交易所上市）、 Vascular Solutions公司（纳斯达克上市公司，他曾任职董事会）的董事（2002年以来）。他持有加州州立大学富勒尔顿分校（California State University, Fullerton）的工商管理学士学位（财务）。他曾担任VivoMetrics公司（私营公司）的董事。VivoMetrics公司于2010年4月根据美国破产法第11章提交了一份请愿书，并于2012年10月摆脱破产。除了前面的句子中描述和下面的披露，在过去十年没有其他事件发生，要求按照S-K规则401f项目披露。
John L. Erb has served as chief executive officer and president of CHF Solutions, Inc. Nasdaq: CHFS since 2015 and as a member of its board of directors and chairman since 2012. He has also served as chief executive officer and chairman of NeuroMedic, Inc., a private company he co-founded, since 2014. Previously, Mr. Erb served as chief executive officer, from 2007 to 2018 of NuAx, Inc. (formerly Cardia Access, Inc.), a private medical device company involved in developing new devices for the treatment of heart disease. Mr. Erb's prior board experience includes service as a director of SenoRx, Inc., then a Nasdaq-listed company, from 2001 until its acquisition in 2010; and as chairman of the board of Vascular Solutions, Inc., then a Nasdaq-listed company, until its acquisition in 2017. Mr. Erb currently serves as chairman of the board of Osprey Medical, Inc. (ASX:OSP) and as a director of MiroMatrix, a private biotechnology company, since 2017. Mr. Erb has a Bachelor of Arts, Business Administration, concentration in finance from California State University. - John L. Erb ，他一直担任Sunshine Heart公司的董事（2012年9月以来），以及董事会主席（2012年10月以来）。他目前担任 Cardia Access公司（医疗设备公司，参与开发新设备用于治疗心脏病）的首席执行官（2007年2月以来）。他于2007年担任CHF Solutions公司（一个医疗设备公司，参与开发、生产和销售治疗充血性心力衰竭的设备）的执行董事会主席。从2001年到2006年，他是CHF Solutions公司的首席执行官。此前，他曾担任IntraTherapeutics公司（医疗设备公司，参与开发、制造和分销外围血管支架）的总裁兼首席执行官（从1997年到2001年）。此前，他曾担任Schneider Worldwide公司（Pfizer公司的一个部门）的全球运营副总裁。他曾担任SenoRx公司（上市公司）的董事（从2001年12月到2010年7月），也曾担任CryoCath Technologies公司（加拿大上市公司）的董事（从2000年10月到2008年12月）。他目前担任Cardia Access公司、Osprey Medical公司（澳大利亚证券交易所上市）、 Vascular Solutions公司（纳斯达克上市公司，他曾任职董事会）的董事（2002年以来）。他持有加州州立大学富勒尔顿分校（California State University, Fullerton）的工商管理学士学位（财务）。他曾担任VivoMetrics公司（私营公司）的董事。VivoMetrics公司于2010年4月根据美国破产法第11章提交了一份请愿书，并于2012年10月摆脱破产。除了前面的句子中描述和下面的披露，在过去十年没有其他事件发生，要求按照S-K规则401f项目披露。
- John L. Erb has served as chief executive officer and president of CHF Solutions, Inc. Nasdaq: CHFS since 2015 and as a member of its board of directors and chairman since 2012. He has also served as chief executive officer and chairman of NeuroMedic, Inc., a private company he co-founded, since 2014. Previously, Mr. Erb served as chief executive officer, from 2007 to 2018 of NuAx, Inc. (formerly Cardia Access, Inc.), a private medical device company involved in developing new devices for the treatment of heart disease. Mr. Erb's prior board experience includes service as a director of SenoRx, Inc., then a Nasdaq-listed company, from 2001 until its acquisition in 2010; and as chairman of the board of Vascular Solutions, Inc., then a Nasdaq-listed company, until its acquisition in 2017. Mr. Erb currently serves as chairman of the board of Osprey Medical, Inc. (ASX:OSP) and as a director of MiroMatrix, a private biotechnology company, since 2017. Mr. Erb has a Bachelor of Arts, Business Administration, concentration in finance from California State University.
- Matthew E. Likens
-
Matthew E. Likens.Matthew E. Likens自2006年7月以来担任我们的总裁，首席执行官兼董事会成员。加入Ulthera之前，他从2001年1月到2006年4月担任无线医疗设备公司GMP Wireless Medicine, Inc.的总裁。他从1978年到2001年在医疗保健公司Baxter Healthcare Corporation担任大量的国内外销售，营销和综合管理职位，包括Baxter Biotech North America的总裁，美国Baxter's Renal Division的总裁。他从Kent State University获得工商管理学士学位。鉴于他是我们的总裁，首席执行官，而且他在制药和医疗技术公司管理职位上有多年的经验，他被选到我们的董事会工作。
Matthew E. Likens has served as a director of the Company since February 2017. Mr. Likens is a principal at Likens Healthcare and Management Consulting, LLC. He was the President and CEO of Ulthera, Inc. from 2006 to 2016. Prior to Ulthera, Mr. Likens was employed at GMP Companies, Inc. as President of GMP Wireless Medicine from 2001 to 2006 and Executive Vice President, Operations from 2001 to 2004. Mr. Likens previously served in various capacities at Baxter Healthcare Corporation from 1978 to 2001 and was President of Baxter’s Renal U.S. business upon his departure in January, 2001. Mr. Likens has a B.B.A. in Marketing from Kent State University. - Matthew E. Likens.Matthew E. Likens自2006年7月以来担任我们的总裁，首席执行官兼董事会成员。加入Ulthera之前，他从2001年1月到2006年4月担任无线医疗设备公司GMP Wireless Medicine, Inc.的总裁。他从1978年到2001年在医疗保健公司Baxter Healthcare Corporation担任大量的国内外销售，营销和综合管理职位，包括Baxter Biotech North America的总裁，美国Baxter's Renal Division的总裁。他从Kent State University获得工商管理学士学位。鉴于他是我们的总裁，首席执行官，而且他在制药和医疗技术公司管理职位上有多年的经验，他被选到我们的董事会工作。
- Matthew E. Likens has served as a director of the Company since February 2017. Mr. Likens is a principal at Likens Healthcare and Management Consulting, LLC. He was the President and CEO of Ulthera, Inc. from 2006 to 2016. Prior to Ulthera, Mr. Likens was employed at GMP Companies, Inc. as President of GMP Wireless Medicine from 2001 to 2006 and Executive Vice President, Operations from 2001 to 2004. Mr. Likens previously served in various capacities at Baxter Healthcare Corporation from 1978 to 2001 and was President of Baxter’s Renal U.S. business upon his departure in January, 2001. Mr. Likens has a B.B.A. in Marketing from Kent State University.
高管简历
中英对照 | 中文 | 英文- Claudia Drayton
Claudia Drayton，2015年1月起，担任本公司的首席财务官、秘书。加入本公司之前，她在 Medtronic, Inc.工作了15年，这是营收达170亿美元的医疗器械行业领导者，担任过各种高级管理职务，后来是在欧洲，担任外周血管业务首席财务官，任期2010-2012；最后，2012-2014，担任综合医疗解决方案首席财务人、高级财务总监；担任上述职务时，她的职责包括盈利性管理、战略规划、并购、规划与预测、财务最佳操作的实施。加入该公司之前，她在 Arthur Andersen担任了7年的审计与商业顾问经理。
Claudia Drayton,has served as Quantum-Si Incorporated Chief Financial Officer since the Closing of the Business Combination (as defined below) in June 2021, and had served as Chief Financial Officer of Legacy Quantum-Si since April 2021. She previously served as Chief Financial Officer of Nuwellis, Inc. (formerly CHF Solutions, Inc.) ("Nuwellis"), a medical device company, from January 2015 to April 2021. During her tenure as Chief Financial Officer of Nuwellis,Ms. Drayton guided the company through the acquisition of its commercial product line, and the completion of several public equity offerings to finance the company's commercial expansion. Prior to joining Nuwellis, Ms. Drayton spent 15 years at Medtronic plc ("Medtronic") a global leader in the medical device industry. During her tenure at Medtronic, Ms. Drayton held multiple senior managerial finance positions, culminating with an assignment in Europe serving as Chief Financial Officer of the peripheral vascular business from 2010 to 2012 and, more recently, as Chief Financial Person of the integrated health solutions business from 2012 to 2014. In these capacities, her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, and implementation of financial best practices. Before joining Medtronic, Ms. Drayton was an audit and business advisory manager at Arthur Andersen LLP for seven years. Ms. Drayton received her M.B.A. from the University of Minnesota's Carlson School of Management and her B.S. from the University of Mary Hardin-Baylor and is a Certified Public Accountant (inactive).- Claudia Drayton，2015年1月起，担任本公司的首席财务官、秘书。加入本公司之前，她在 Medtronic, Inc.工作了15年，这是营收达170亿美元的医疗器械行业领导者，担任过各种高级管理职务，后来是在欧洲，担任外周血管业务首席财务官，任期2010-2012；最后，2012-2014，担任综合医疗解决方案首席财务人、高级财务总监；担任上述职务时，她的职责包括盈利性管理、战略规划、并购、规划与预测、财务最佳操作的实施。加入该公司之前，她在 Arthur Andersen担任了7年的审计与商业顾问经理。
- Claudia Drayton,has served as Quantum-Si Incorporated Chief Financial Officer since the Closing of the Business Combination (as defined below) in June 2021, and had served as Chief Financial Officer of Legacy Quantum-Si since April 2021. She previously served as Chief Financial Officer of Nuwellis, Inc. (formerly CHF Solutions, Inc.) ("Nuwellis"), a medical device company, from January 2015 to April 2021. During her tenure as Chief Financial Officer of Nuwellis,Ms. Drayton guided the company through the acquisition of its commercial product line, and the completion of several public equity offerings to finance the company's commercial expansion. Prior to joining Nuwellis, Ms. Drayton spent 15 years at Medtronic plc ("Medtronic") a global leader in the medical device industry. During her tenure at Medtronic, Ms. Drayton held multiple senior managerial finance positions, culminating with an assignment in Europe serving as Chief Financial Officer of the peripheral vascular business from 2010 to 2012 and, more recently, as Chief Financial Person of the integrated health solutions business from 2012 to 2014. In these capacities, her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, and implementation of financial best practices. Before joining Medtronic, Ms. Drayton was an audit and business advisory manager at Arthur Andersen LLP for seven years. Ms. Drayton received her M.B.A. from the University of Minnesota's Carlson School of Management and her B.S. from the University of Mary Hardin-Baylor and is a Certified Public Accountant (inactive).
- John L. Erb
John L. Erb ，他一直担任Sunshine Heart公司的董事（2012年9月以来），以及董事会主席（2012年10月以来）。他目前担任 Cardia Access公司（医疗设备公司，参与开发新设备用于治疗心脏病）的首席执行官（2007年2月以来）。他于2007年担任CHF Solutions公司（一个医疗设备公司，参与开发、生产和销售治疗充血性心力衰竭的设备）的执行董事会主席。从2001年到2006年，他是CHF Solutions公司的首席执行官。此前，他曾担任IntraTherapeutics公司（医疗设备公司，参与开发、制造和分销外围血管支架）的总裁兼首席执行官（从1997年到2001年）。此前，他曾担任Schneider Worldwide公司（Pfizer公司的一个部门）的全球运营副总裁。他曾担任SenoRx公司（上市公司）的董事（从2001年12月到2010年7月），也曾担任CryoCath Technologies公司（加拿大上市公司）的董事（从2000年10月到2008年12月）。他目前担任Cardia Access公司、Osprey Medical公司（澳大利亚证券交易所上市）、 Vascular Solutions公司（纳斯达克上市公司，他曾任职董事会）的董事（2002年以来）。他持有加州州立大学富勒尔顿分校（California State University, Fullerton）的工商管理学士学位（财务）。他曾担任VivoMetrics公司（私营公司）的董事。VivoMetrics公司于2010年4月根据美国破产法第11章提交了一份请愿书，并于2012年10月摆脱破产。除了前面的句子中描述和下面的披露，在过去十年没有其他事件发生，要求按照S-K规则401f项目披露。
John L. Erb has served as chief executive officer and president of CHF Solutions, Inc. Nasdaq: CHFS since 2015 and as a member of its board of directors and chairman since 2012. He has also served as chief executive officer and chairman of NeuroMedic, Inc., a private company he co-founded, since 2014. Previously, Mr. Erb served as chief executive officer, from 2007 to 2018 of NuAx, Inc. (formerly Cardia Access, Inc.), a private medical device company involved in developing new devices for the treatment of heart disease. Mr. Erb's prior board experience includes service as a director of SenoRx, Inc., then a Nasdaq-listed company, from 2001 until its acquisition in 2010; and as chairman of the board of Vascular Solutions, Inc., then a Nasdaq-listed company, until its acquisition in 2017. Mr. Erb currently serves as chairman of the board of Osprey Medical, Inc. (ASX:OSP) and as a director of MiroMatrix, a private biotechnology company, since 2017. Mr. Erb has a Bachelor of Arts, Business Administration, concentration in finance from California State University.- John L. Erb ，他一直担任Sunshine Heart公司的董事（2012年9月以来），以及董事会主席（2012年10月以来）。他目前担任 Cardia Access公司（医疗设备公司，参与开发新设备用于治疗心脏病）的首席执行官（2007年2月以来）。他于2007年担任CHF Solutions公司（一个医疗设备公司，参与开发、生产和销售治疗充血性心力衰竭的设备）的执行董事会主席。从2001年到2006年，他是CHF Solutions公司的首席执行官。此前，他曾担任IntraTherapeutics公司（医疗设备公司，参与开发、制造和分销外围血管支架）的总裁兼首席执行官（从1997年到2001年）。此前，他曾担任Schneider Worldwide公司（Pfizer公司的一个部门）的全球运营副总裁。他曾担任SenoRx公司（上市公司）的董事（从2001年12月到2010年7月），也曾担任CryoCath Technologies公司（加拿大上市公司）的董事（从2000年10月到2008年12月）。他目前担任Cardia Access公司、Osprey Medical公司（澳大利亚证券交易所上市）、 Vascular Solutions公司（纳斯达克上市公司，他曾任职董事会）的董事（2002年以来）。他持有加州州立大学富勒尔顿分校（California State University, Fullerton）的工商管理学士学位（财务）。他曾担任VivoMetrics公司（私营公司）的董事。VivoMetrics公司于2010年4月根据美国破产法第11章提交了一份请愿书，并于2012年10月摆脱破产。除了前面的句子中描述和下面的披露，在过去十年没有其他事件发生，要求按照S-K规则401f项目披露。
- John L. Erb has served as chief executive officer and president of CHF Solutions, Inc. Nasdaq: CHFS since 2015 and as a member of its board of directors and chairman since 2012. He has also served as chief executive officer and chairman of NeuroMedic, Inc., a private company he co-founded, since 2014. Previously, Mr. Erb served as chief executive officer, from 2007 to 2018 of NuAx, Inc. (formerly Cardia Access, Inc.), a private medical device company involved in developing new devices for the treatment of heart disease. Mr. Erb's prior board experience includes service as a director of SenoRx, Inc., then a Nasdaq-listed company, from 2001 until its acquisition in 2010; and as chairman of the board of Vascular Solutions, Inc., then a Nasdaq-listed company, until its acquisition in 2017. Mr. Erb currently serves as chairman of the board of Osprey Medical, Inc. (ASX:OSP) and as a director of MiroMatrix, a private biotechnology company, since 2017. Mr. Erb has a Bachelor of Arts, Business Administration, concentration in finance from California State University.